Anti-CD20 for rheumatoid arthritis

被引：0
|
作者：
Edwards, JC [1 ]
Leandro, MJ [1 ]
Cambridge, G [1 ]
机构：
[1] UCL, London, England
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2004年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：25 / 25
页数：1
相关论文
共 50 条
  • [21] Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis
    Roll, Petra
    Palanichamy, Arumugam
    Kneitz, Christian
    Dorner, Thomas
    Tony, Hans-Peter
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (08): : 2377 - 2386
  • [22] Maintained response to treatment with anti-CD20 antibodies (Rituximab) in a case autoimmune haemolytic anaemia associated with rheumatoid arthritis.
    Barquero-Romero, J
    Domínguez, MG
    Miranda, MP
    [J]. MEDICINA CLINICA, 2005, 124 (13): : 517 - 518
  • [23] Anti-CD20 therapy in patients with rheumatoid arthritis -: Predictors of response and B cell subset regeneration after repeated treatment
    Roll, Petra
    Doerner, Thomas
    Tony, Hans-Peter
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (06): : 1566 - 1575
  • [24] Epstein-Barr virus (EBV) in bone marrow of patients with rheumatoid arthritis predicts response to anti-CD20 treatment
    Tarkowski, Andrej
    Zendjanchi, Kiandokht
    Bertilsson, Lennart
    Lindholm, Catharina
    Bergstrom, Tomas
    Bokarewa, Maria
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2008, 37 : 38 - 38
  • [25] Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial
    Ng, CM
    Bruno, R
    Combs, D
    Davies, B
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (07): : 792 - 801
  • [26] Risk of infections and malignancies after treatment with anti-CD20 monoclonal antibodies: ocrelizumab and rituximab in rheumatoid arthritis and multiple sclerosis
    Kappos, L.
    Leppert, D.
    Tinbergen, J.
    Gerber, M.
    Hauser, S. L.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 424 - 424
  • [27] Monitoring of gene expression in patients with rheumatoid arthritis treated with anti-CD20 (Rituximab) applying DNA-CHIP technology
    Drynda, S.
    Drynda, A.
    Koczan, D.
    Thiesen, H.
    Kekow, J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 188 - 189
  • [28] Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti-CD20 therapy: the B-cell roadblock hypothesis
    Silverman, Gregg J.
    Boyle, David L.
    [J]. IMMUNOLOGICAL REVIEWS, 2008, 223 : 175 - 185
  • [29] Is there a role for anti-CD20 antibodies in CLL?
    Shah, Harsh R.
    Stephens, Deborah M.
    [J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2021, (01) : 68 - 75
  • [30] Anti-CD20 patent battle ends
    Laura DeFrancesco
    [J]. Nature Biotechnology, 2010, 28 (8) : 769 - 769
12345